{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:24:37Z","timestamp":1783607077572,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Municipal Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05260-8","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:18:08Z","timestamp":1783599488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant\/neuroendocrine phenotype"],"prefix":"10.1007","author":[{"given":"Huan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"6","key":"5260_CR1","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","volume":"22","author":"AM Aparicio","year":"2016","unstructured":"Aparicio AM, Shen L, Tapia EL et al (2016) Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res 22(6):1520\u20131530","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5260_CR2","doi-asserted-by":"publisher","first-page":"e2021692","DOI":"10.1001\/jamanetworkopen.2020.21692","volume":"3","author":"S Schmid","year":"2020","unstructured":"Schmid S, Omlin A, Higano C et al (2020) Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations. JAMA Netw Open 3(10):e2021692","journal-title":"JAMA Netw Open"},{"issue":"3","key":"5260_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/JU.0000000000001819","volume":"206","author":"L Fan","year":"2021","unstructured":"Fan L, Fei X, Zhu Y et al (2021) Distinct response to platinum-based chemotherapy among patients with metastatic castration-resistant prostate cancer harboring alterations in genes involved in homologous recombination. J Urol 206(3):630\u2013637","journal-title":"J Urol"},{"issue":"12","key":"5260_CR4","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/cncr.33487","volume":"127","author":"DH Kwon","year":"2021","unstructured":"Kwon DH, Chou J, Yip SM et al (2021) Differential treatment outcomes in BRCA1\/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer 127(12):1965\u20131973","journal-title":"Cancer"},{"key":"5260_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/PO.19.00346","volume":"4","author":"JM Mota","year":"2020","unstructured":"Mota JM, Barnett E, Nauseef JT et al (2020) Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations. JCO Precis Oncol 4:355\u2013366","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"5260_CR6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","volume":"20","author":"PG Corn","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A et al (2019) Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432\u20131443","journal-title":"Lancet Oncol"},{"issue":"3","key":"5260_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.euo.2023.09.001","volume":"7","author":"T Fazekas","year":"2024","unstructured":"Fazekas T, Sz\u00e9les \u00c1D, Teutsch B et al (2024) Poly (ADP-ribose) polymerase inhibitors have comparable efficacy with platinum chemotherapy in patients with BRCA-positive metastatic castration-resistant prostate cancer. A systematic review and meta-analysis. Eur Urol Oncol 7(3):365\u2013375","journal-title":"Eur Urol Oncol"},{"key":"5260_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.026","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Cheng HH, Gulati R et al (2025) Results from a phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in the treatment of patients with metastatic castration-resistant prostate cancer with DNA homologous recombination repair deficiency. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2025.04.026","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"5260_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.clgc.2023.04.008","volume":"21","author":"CJ Eule","year":"2023","unstructured":"Eule CJ, Hu J, Al-Saad S et al (2023) Outcomes of second-line therapies in patients with metastatic de novo and treatment-emergent neuroendocrine prostate cancer: a multi-institutional study. Clin Genitourin Cancer 21(4):483\u2013490","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"5260_CR10","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.21873\/anticanres.16571","volume":"43","author":"N Fujimoto","year":"2023","unstructured":"Fujimoto N, Tsubonuma Y, Nagata Y et al (2023) Second-line systemic therapy for highly aggressive neuroendocrine prostate cancer. Anticancer Res 43(9):3841\u20133847","journal-title":"Anticancer Res"},{"key":"5260_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW et al (2019) Clinical features of neuroendocrine prostate cancer. Eur J Cancer 121:7\u201318","journal-title":"Eur J Cancer"},{"issue":"1","key":"5260_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.18632\/oncotarget.26523","volume":"10","author":"L Apostolidis","year":"2019","unstructured":"Apostolidis L, Nientiedt C, Winkler EC et al (2019) Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget 10(1):17\u201329","journal-title":"Oncotarget"},{"issue":"4","key":"5260_CR13","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.21873\/anticanres.15699","volume":"42","author":"H Iwamoto","year":"2022","unstructured":"Iwamoto H, Nakagawa R, Makino T et al (2022) Treatment outcomes in neuroendocrine prostate cancer. Anticancer Res 42(4):2167\u20132176","journal-title":"Anticancer Res"},{"issue":"12","key":"5260_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123792","volume":"12","author":"N Spetsieris","year":"2020","unstructured":"Spetsieris N, Boukovala M, Patsakis G, Alafis I, Efstathiou E (2020) Neuroendocrine and aggressive-variant prostate cancer. Cancers (Basel) 12(12):3792","journal-title":"Cancers (Basel)"},{"issue":"2","key":"5260_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/oncolo\/oyac198","volume":"28","author":"NM Hawkey","year":"2023","unstructured":"Hawkey NM, Broderick A, George DJ, Sartor O, Armstrong AJ (2023) The value of phenotypic precision medicine in prostate cancer. Oncologist 28(2):93\u2013104","journal-title":"Oncologist"},{"key":"5260_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158199","author":"RC Kiss","year":"2021","unstructured":"Kiss RC, Xia F, Acklin S (2021) Targeting DNA damage response and repair to enhance therapeutic index in cisplatin-based cancer treatment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22158199","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5260_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","volume":"69","author":"HH Cheng","year":"2016","unstructured":"Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B (2016) Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 69(6):992\u2013995","journal-title":"Eur Urol"},{"issue":"18","key":"5260_CR18","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1002\/cncr.30808","volume":"123","author":"MM Pomerantz","year":"2017","unstructured":"Pomerantz MM, Spis\u00e1k S, Jia L et al (2017) The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 123(18):3532\u20133539","journal-title":"Cancer"},{"issue":"1","key":"5260_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.eururo.2018.09.048","volume":"75","author":"Z Zafeiriou","year":"2019","unstructured":"Zafeiriou Z, Bianchini D, Chandler R et al (2019) Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Eur Urol 75(1):184\u2013192","journal-title":"Eur Urol"},{"issue":"14","key":"5260_CR20","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah J, Xu J, Weinstock C et al (2024) Efficacy of Poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US food and drug Administration pooled analysis. J Clin Oncol 42(14):1687\u20131698","journal-title":"J Clin Oncol"},{"issue":"7","key":"5260_CR21","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu YM, Cie\u015blik M, Lonigro RJ et al (2018) Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173(7):1770-1782.e14","journal-title":"Cell"},{"key":"5260_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2019.03.001","volume":"75","author":"I Tsaur","year":"2019","unstructured":"Tsaur I, Heidegger I, Kretschmer A et al (2019) Aggressive variants of prostate cancer\u2014are we ready to apply specific treatment right now. Cancer Treat Rev 75:20\u201326","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"5260_CR23","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","volume":"19","author":"AM Aparicio","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG et al (2013) Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621\u20133630","journal-title":"Clin Cancer Res"},{"issue":"6320","key":"5260_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y et al (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355(6320):78\u201383","journal-title":"Science"},{"key":"5260_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1191311","volume":"14","author":"J Imamura","year":"2023","unstructured":"Imamura J, Ganguly S, Muskara A et al (2023) Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution. Front Endocrinol (Lausanne) 14:1191311","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5260_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010318","author":"M Pedrani","year":"2025","unstructured":"Pedrani M, Barizzi J, Salfi G et al (2025) The emerging predictive and prognostic role of aggressive-variant-associated tumor suppressor genes across prostate cancer stages. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26010318","journal-title":"Int J Mol Sci"},{"key":"5260_CR27","unstructured":"SWOG S2312 \/ NCT06470243. A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature. ClinicalTrials.gov Identifier: NCT06470243. Activated September 3, 2024. (Accessed January 2026)."},{"issue":"2","key":"5260_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.clgc.2023.12.016","volume":"22","author":"K van der Zande","year":"2024","unstructured":"van der Zande K, Tutuhatunewa-Louhanepessy RD, Hamberg P et al (2024) Combined cabazitaxel and carboplatin treatment of metastatic castration resistant prostate cancer patients, with innate or acquired resistance to cabazitaxel monotherapy. Clin Genitourin Cancer 22(2):445-453.e1","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"5260_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/10408363.2023.2266482","volume":"61","author":"P Slootbeek","year":"2024","unstructured":"Slootbeek P, Tolmeijer SH, Mehra N, Schalken JA (2024) Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter. Crit Rev Clin Lab Sci 61(3):178\u2013204","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"3","key":"5260_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.eururo.2024.05.025","volume":"87","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, DeJong M, Rettig M et al (2025) Docetaxel and carboplatin for the treatment of patients with metastatic castration-resistant prostate cancer and biallelic inactivation of genes in the homologous recombination DNA repair pathway: the ABCD trial. Eur Urol 87(3):375\u2013376","journal-title":"Eur Urol"},{"key":"5260_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241229876","volume":"16","author":"E Coquan","year":"2024","unstructured":"Coquan E, Penel N, Lequesne J et al (2024) Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial. Ther Adv Urol 16:17562872241229876","journal-title":"Ther Adv Urol"},{"key":"5260_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00310","volume":"9","author":"M Aldea","year":"2025","unstructured":"Aldea M, Orillard E, Bernard-Tessier A et al (2025) Activity of platinum monotherapy in patients with metastatic castration-resistant prostate cancer and DNA damage repair gene alterations. JCO Precis Oncol 9:e2500310","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"5260_CR33","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.3390\/cancers15102814","volume":"15","author":"P Slootbeek","year":"2023","unstructured":"Slootbeek P, Kloots I, van Oort IM et al (2023) Cross-resistance between platinum-based chemotherapy and parp inhibitors in castration-resistant prostate cancer. Cancers (Basel) 15(10):2814","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5260_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00526-9","volume":"8","author":"CS Walmsley","year":"2024","unstructured":"Walmsley CS, Jonsson P, Cheng ML et al (2024) Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. npj Precis Oncol 8(1):34","journal-title":"npj Precis Oncol"},{"key":"5260_CR35","first-page":"17","volume":"2","author":"HH Cheng","year":"2018","unstructured":"Cheng HH, Salipante SJ, Nelson PS, Montgomery B, Pritchard CC (2018) Polyclonal BRCA2 reversion mutations detected in circulating tumor dna after platinum chemotherapy in a patient with metastatic prostate cancer. JCO Precis Oncol 2:17","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"5260_CR36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","volume":"7","author":"D Quigley","year":"2017","unstructured":"Quigley D, Alumkal JJ, Wyatt AW et al (2017) Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov 7(9):999\u20131005","journal-title":"Cancer Discov"},{"issue":"10","key":"5260_CR37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N et al (2023) Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(10):1067\u20131096","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"5260_CR38","volume":"9","author":"I Nogueira Costa","year":"2022","unstructured":"Nogueira Costa I, Reis J, Meireles S, Ribeiro MJ, Barbosa M, Augusto I (2022) Metastatic castration-resistant prostate cancer with BRCA2 mutation: the challenge incorporating PARP inhibitors and platinum in treatment sequencing. Eur J Case Rep Intern Med 9(5):003331","journal-title":"Eur J Case Rep Intern Med"},{"issue":"6","key":"5260_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","volume":"87","author":"S Naqvi","year":"2025","unstructured":"Naqvi S, Riaz IB, Bibi A et al (2025) Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis. Eur Urol 87(6):626\u2013640","journal-title":"Eur Urol"},{"issue":"14","key":"5260_CR40","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1200\/JCO.2002.12.065","volume":"20","author":"CN Papandreou","year":"2002","unstructured":"Papandreou CN, Daliani DD, Thall PF et al (2002) Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20(14):3072\u20133080","journal-title":"J Clin Oncol"},{"issue":"3","key":"5260_CR41","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.juro.2007.05.044","volume":"178","author":"S Culine","year":"2007","unstructured":"Culine S, El Demery M, Lamy PJ, Iborra F, Avanc\u00e8s C, Pinguet F (2007) Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178(3):844\u2013848","journal-title":"J Urol"},{"issue":"4","key":"5260_CR42","doi-asserted-by":"publisher","first-page":"e00032","DOI":"10.1097\/JU9.0000000000000138","volume":"2","author":"AH Bryce","year":"2024","unstructured":"Bryce AH, Crawford ED, Agarwal N et al (2024) Expert perspectives on controversies in metastatic castration-resistant prostate cancer management: narrative review and report of the first us prostate cancer conference part 2. JU Open Plus. 2(4):e00032","journal-title":"JU Open Plus."},{"issue":"10","key":"5260_CR43","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M et al (2023) Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 24(10):1094\u20131108","journal-title":"Lancet Oncol"},{"issue":"18","key":"5260_CR44","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR et al (2023) Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol 41(18):3339\u20133351","journal-title":"J Clin Oncol"},{"issue":"10398","key":"5260_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J et al (2023) Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402(10398):291\u2013303","journal-title":"Lancet"},{"issue":"22","key":"5260_CR46","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091\u20132102","journal-title":"N Engl J Med"},{"issue":"32","key":"5260_CR47","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida W, Patnaik A, Campbell D et al (2020) Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 38(32):3763\u20133772","journal-title":"J Clin Oncol"},{"issue":"26","key":"5260_CR48","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381(26):2506\u20132518","journal-title":"N Engl J Med"},{"key":"5260_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102818","volume":"130","author":"E Akkus","year":"2024","unstructured":"Akkus E, Arslan \u00c7, \u00dcr\u00fcn Y (2024) Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: insights and perspectives. Cancer Treat Rev 130:102818","journal-title":"Cancer Treat Rev"},{"issue":"10314","key":"5260_CR50","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H et al (2021) Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 398(10314):1894\u20131904","journal-title":"Lancet"},{"issue":"8","key":"5260_CR51","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","volume":"19","author":"A Kitchlu","year":"2024","unstructured":"Kitchlu A, Silva V, Anand S et al (2024) Assessment of GFR in patients with cancer: a statement from the American Society of Onco-Nephrology. Clin J Am Soc Nephrol 19(8):1061\u20131072","journal-title":"Clin J Am Soc Nephrol"},{"issue":"28","key":"5260_CR52","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1200\/JCO.22.02768","volume":"41","author":"AH Calvert","year":"2023","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (2023) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 41(28):4453\u20134454","journal-title":"J Clin Oncol"},{"issue":"28","key":"5260_CR53","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger M, Hardy-Bessard AC, Kim CS et al (2017) Phase III study comparing a reduced dose of Cabazitaxel (20 mg\/m(2)) and the currently approved dose (25 mg\/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 35(28):3198\u20133206","journal-title":"J Clin Oncol"},{"issue":"28","key":"5260_CR54","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"21","key":"5260_CR55","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167","journal-title":"J Clin Oncol"},{"issue":"24","key":"5260_CR56","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782\u20132797","journal-title":"J Clin Oncol"},{"issue":"7","key":"5260_CR57","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7):1148\u20131159","journal-title":"J Clin Oncol"},{"issue":"6","key":"5260_CR58","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","volume":"34","author":"TL Lotan","year":"2021","unstructured":"Lotan TL, Kaur HB, Salles DC et al (2021) Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol 34(6):1185\u20131193","journal-title":"Mod Pathol"},{"issue":"1","key":"5260_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04515-8","volume":"21","author":"A Crippa","year":"2020","unstructured":"Crippa A, De Laere B, Discacciati A et al (2020) The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials 21(1):579","journal-title":"Trials"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05260-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05260-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05260-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:03:27Z","timestamp":1783605807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05260-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":59,"alternative-id":["5260"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05260-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"During the preparation of this work, the first author used ChatGPT (OpenAI) in order to refine the English language, improve clarity and academic style, and check grammar and punctuation. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process"}}]}}